JP4615311B2 - ウイルスベクターおよびその遺伝子治療のための使用 - Google Patents
ウイルスベクターおよびその遺伝子治療のための使用 Download PDFInfo
- Publication number
- JP4615311B2 JP4615311B2 JP2004544141A JP2004544141A JP4615311B2 JP 4615311 B2 JP4615311 B2 JP 4615311B2 JP 2004544141 A JP2004544141 A JP 2004544141A JP 2004544141 A JP2004544141 A JP 2004544141A JP 4615311 B2 JP4615311 B2 JP 4615311B2
- Authority
- JP
- Japan
- Prior art keywords
- vector
- sequence
- tumor
- cells
- vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001415 gene therapy Methods 0.000 title description 14
- 239000013603 viral vector Substances 0.000 title description 6
- 239000013598 vector Substances 0.000 claims description 110
- 206010028980 Neoplasm Diseases 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 241000700605 Viruses Species 0.000 claims description 42
- 102000013462 Interleukin-12 Human genes 0.000 claims description 39
- 108010065805 Interleukin-12 Proteins 0.000 claims description 39
- 108010002350 Interleukin-2 Proteins 0.000 claims description 29
- 102000000588 Interleukin-2 Human genes 0.000 claims description 29
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 27
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 27
- 239000002245 particle Substances 0.000 claims description 26
- 150000007523 nucleic acids Chemical group 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000000875 corresponding effect Effects 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 230000003308 immunostimulating effect Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000010586 diagram Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 14
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100406366 Caenorhabditis elegans pad-2 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 1
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 101150108558 PAD1 gene Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10248141A DE10248141B4 (de) | 2002-10-11 | 2002-10-11 | Nukleinsäuren und deren Verwendung für die Gentherapie |
| PCT/EP2003/011252 WO2004035799A2 (de) | 2002-10-11 | 2003-10-10 | Virale vektoren und deren verwendung für die gentherapie |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010192832A Division JP2011036251A (ja) | 2002-10-11 | 2010-08-30 | ウイルスベクターおよびその遺伝子治療のための使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006511212A JP2006511212A (ja) | 2006-04-06 |
| JP2006511212A5 JP2006511212A5 (OSRAM) | 2006-11-24 |
| JP4615311B2 true JP4615311B2 (ja) | 2011-01-19 |
Family
ID=32102775
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544141A Expired - Fee Related JP4615311B2 (ja) | 2002-10-11 | 2003-10-10 | ウイルスベクターおよびその遺伝子治療のための使用 |
| JP2010192832A Pending JP2011036251A (ja) | 2002-10-11 | 2010-08-30 | ウイルスベクターおよびその遺伝子治療のための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010192832A Pending JP2011036251A (ja) | 2002-10-11 | 2010-08-30 | ウイルスベクターおよびその遺伝子治療のための使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8067227B2 (OSRAM) |
| EP (1) | EP1556411B1 (OSRAM) |
| JP (2) | JP4615311B2 (OSRAM) |
| AU (1) | AU2003273983A1 (OSRAM) |
| CY (1) | CY1114777T1 (OSRAM) |
| DE (1) | DE10248141B4 (OSRAM) |
| DK (1) | DK1556411T3 (OSRAM) |
| ES (1) | ES2440951T3 (OSRAM) |
| PT (1) | PT1556411E (OSRAM) |
| SI (1) | SI1556411T1 (OSRAM) |
| WO (1) | WO2004035799A2 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
| DE102005055128B4 (de) * | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| ES2888249T3 (es) | 2011-10-11 | 2022-01-03 | Univ Zuerich | Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| SG10201913163PA (en) | 2015-12-18 | 2020-03-30 | Oncosec Medical Inc | Plasmid constructs for heterologous protein expression and methods of use |
| EP3211000B1 (en) * | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
| EP3458083B1 (en) | 2016-05-18 | 2022-11-02 | ModernaTX, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
| UY37621A (es) | 2017-02-28 | 2018-09-28 | Sanofi Sa | Arn terapéutico que codifica citoquinas |
| MX2019013071A (es) | 2017-05-02 | 2019-12-11 | Nektar Therapeutics | Metodo de tratamiento inmunoterapeutico de un tumor. |
| US20220347244A1 (en) * | 2018-01-19 | 2022-11-03 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
| US11230699B2 (en) * | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| WO2000041508A2 (en) | 1999-01-15 | 2000-07-20 | Mount Sinai School Of Medicine Of The City University Of New York | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
| KR20020010206A (ko) * | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신 |
| EP2336339A3 (en) * | 2000-09-25 | 2011-09-14 | The Regents of the University of Michigan | Production of viral vectors |
-
2002
- 2002-10-11 DE DE10248141A patent/DE10248141B4/de not_active Expired - Fee Related
-
2003
- 2003-10-10 AU AU2003273983A patent/AU2003273983A1/en not_active Abandoned
- 2003-10-10 DK DK03757951.3T patent/DK1556411T3/da active
- 2003-10-10 ES ES03757951.3T patent/ES2440951T3/es not_active Expired - Lifetime
- 2003-10-10 PT PT37579513T patent/PT1556411E/pt unknown
- 2003-10-10 US US10/530,706 patent/US8067227B2/en not_active Expired - Fee Related
- 2003-10-10 SI SI200332329T patent/SI1556411T1/sl unknown
- 2003-10-10 EP EP03757951.3A patent/EP1556411B1/de not_active Expired - Lifetime
- 2003-10-10 JP JP2004544141A patent/JP4615311B2/ja not_active Expired - Fee Related
- 2003-10-10 WO PCT/EP2003/011252 patent/WO2004035799A2/de not_active Ceased
-
2010
- 2010-08-30 JP JP2010192832A patent/JP2011036251A/ja active Pending
-
2013
- 2013-12-27 CY CY20131101171T patent/CY1114777T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004035799A3 (de) | 2004-06-10 |
| WO2004035799A2 (de) | 2004-04-29 |
| JP2006511212A (ja) | 2006-04-06 |
| PT1556411E (pt) | 2014-01-07 |
| US8067227B2 (en) | 2011-11-29 |
| DE10248141A1 (de) | 2004-09-02 |
| AU2003273983A8 (en) | 2004-05-04 |
| SI1556411T1 (sl) | 2014-01-31 |
| ES2440951T3 (es) | 2014-01-31 |
| DE10248141B4 (de) | 2007-04-19 |
| JP2011036251A (ja) | 2011-02-24 |
| AU2003273983A1 (en) | 2004-05-04 |
| US20060153805A1 (en) | 2006-07-13 |
| CY1114777T1 (el) | 2016-12-14 |
| EP1556411B1 (de) | 2013-10-02 |
| EP1556411A2 (de) | 2005-07-27 |
| DK1556411T3 (da) | 2014-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011036251A (ja) | ウイルスベクターおよびその遺伝子治療のための使用 | |
| Cai et al. | Heterologous prime-boost enhances the antitumor immune response elicited by plant-virus-based cancer vaccine | |
| CN111658670B (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
| Wille-Reece et al. | Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses | |
| JP4723722B2 (ja) | ワクチン用アジュバントとしてのｍｈｃクラスｉｉリガンドの使用および癌治療におけるｌａｇ−３の使用 | |
| JPH06508039A (ja) | 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス | |
| KR100911624B1 (ko) | Ｉｌ－１２ 및 ｉｌ－２３의 효율적인 공동발현 방법 | |
| JP2002511846A (ja) | Ｈｓｖアンプリコンベクターによる自家腫瘍ワクチンの迅速な産生 | |
| CN100425287C (zh) | 肿瘤疫苗 | |
| US12234261B2 (en) | Hepatitis B vaccines and uses of the same | |
| JPH10505339A (ja) | 腫瘍疾患の治療のための生ワクチン | |
| Moran et al. | Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice | |
| Van Tendeloo et al. | Gene-based cancer vaccines: an ex vivo approach | |
| Lopez et al. | IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis | |
| JP2023550480A (ja) | ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用 | |
| Cheng et al. | Selective delivery of augmented IL-2 receptor signals to responding CD8+ T cells increases the size of the acute antiviral response and of the resulting memory T cell pool | |
| RU2739073C2 (ru) | Новые медицинские агенты и их применение | |
| JP2007523093A (ja) | 非ＣｐＧ核酸を使用した全身性免疫活性化法 | |
| Liu et al. | Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression | |
| Qing et al. | Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice | |
| Liu et al. | Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity | |
| Fujii et al. | Augmented systemic immunity in mice implanted with tumor necrosis factor‐α gene‐transduced Meth‐A cells | |
| Couty et al. | Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine | |
| CN120789259A (zh) | 一种增强腺病毒疫苗抗肿瘤效应的方法 | |
| Hung | The central role of CD4+ T cells in the generation of a maximal systemic antitumor response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061006 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070411 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070411 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20081127 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20081205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091210 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100830 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101008 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101020 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4615311 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |